Gilead withdraws bladder cancer drug in US after failed trial
(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial. The decision was made in consultation with the U.S. health regulator, the company said. The U.S. Food and Drug Administration had granted …
Gilead withdraws bladder cancer drug in US after failed trial Read More »










